.avif)
EGFR vIII Mutation Test - Brain Tumor Biomarker
Detects the EGFR vIII mutation — a tumor-specific EGFR alteration most commonly found in glioblastoma — to guide treatment selection and prognosis. Identifying EGFRvIII can help avoid ineffective therapies and delays in care, enabling targeted treatment decisions that may reduce tumor progression and recurrence.
MGMT Methylation Test - Brain Tumor Biomarker
The MGMT promoter methylation test detects whether the MGMT DNA-repair gene is epigenetically silenced in a tumor—information that predicts better response to alkylating chemotherapy (like temozolomide) in aggressive brain cancers such as glioblastoma. Knowing this status helps guide treatment choices so patients can avoid ineffective chemotherapy and its unnecessary side effects while pursuing more effective, personalized care.
1p/19q Codeletion Test - Brain Tumor Biomarker
Detects whether a brain tumor (especially suspected oligodendroglioma) has the 1p/19q co‑deletion—a diagnostic and prognostic marker that predicts better response to chemo/radiation. Knowing this guides targeted treatment, helping avoid ineffective therapies or delays that can lead to tumor progression and worsening neurological outcomes.
IDH2 Mutation Test - Brain Tumor Biomarker
A fast genetic test that detects IDH2 mutations commonly found in acute myeloid leukemia and other myeloid cancers to guide targeted therapy decisions. Early identification of an IDH2 mutation enables personalized treatment and monitoring, which may reduce the risk of ineffective therapies, disease progression, and relapse.
IDH1 Mutation Test - Brain Tumor Biomarker
Detects mutations in the IDH1 gene commonly found in gliomas, acute myeloid leukemia and intrahepatic cholangiocarcinoma, helping confirm diagnosis and identify eligibility for targeted IDH1 therapies. By enabling earlier, more precise treatment and monitoring, the test may reduce the risk of inappropriate therapy and help limit disease progression or relapse.
.svg)
